COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Butrans for Treatment of Restless Legs Syndrome (Butrans)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02138357
Recruitment Status : Withdrawn (No funding)
First Posted : May 14, 2014
Last Update Posted : January 7, 2015
Sponsor:
Information provided by (Responsible Party):
John Winkelman, MD, PhD, Massachusetts General Hospital

Brief Summary:

The primary objective of the study is to determine whether Butrans Transdermal System (BTDS) reduces RLS symptom severity in patients with moderate to severe idiopathic RLS who are naïve to opiate treatment.

The secondary objective of the study is to investigate the effects of BTDS on mood, sleep, and quality of life.

The study will consist of nine visits. Depending on the need for medication titration, there may also be two scheduled telephone contacts.

Visit 1: This is a screening visit to determine study eligibility. Eligible subjects who choose to participate must undergo medication washout as described in the detailed protocol between visits 1 and 2.

Treatment period #1 (Visits 2 - 5; day 0 - 28): Baseline measures will be recorded and subjects randomized to treatment order at visit 2 (day 0). Study medication as well as rescue medication (l-dopa, a non-blinded active treatment to be used within a limited dose range as described in the detailed protocol) will be dispensed. Subjects will begin treatment period #1 immediately after this. The study medication will be titrated within the allowed range according to subject's reported symptoms during visit 3 (day 7), visit 4 (day 14), telephone contact (day 21). Visit 5 will occur on day 28 and will include assessment of outcome measures for the first treatment period. Visit 5 will also mark the beginning of the second treatment period.

Treatment period #2 (Visits 6 - 8; day 28 - 56): Procedures will be similar to those described above during treatment period #1. Visit 8 will mark the end of the second treatment period during which outcome measures will be ascertained.

Follow up visit (Visit 9; day 70): This will be a safety follow-up visit approximately two weeks after visit 8 for review of adverse events.


Condition or disease Intervention/treatment Phase
Restless Legs Syndrome Drug: buprenorphine transdermal delivery system (BTDS) Drug: Placebo for BTDS patch Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Butrans for Treatment of Restless Legs Syndrome
Study Start Date : December 2014
Estimated Primary Completion Date : December 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Restless Legs

Arm Intervention/treatment
Placebo Comparator: Placebo Patch

The Placebo is in the form of a patch. We will be using placebo patches labeled 5mcg/hour, 10mcg/hour, and 20mcg/hour that will be changed every 7 days.

Each subject will participate in this arm of the study for four weeks.

Drug: buprenorphine transdermal delivery system (BTDS)
Other Name: Butrans

Drug: Placebo for BTDS patch
A placebo patch will be manufactured to mimic the BTDS patch.

Experimental: buprenorphine transdermal delivery system (BTDS)

buprenorphine transdermal delivery system (BTDS), brand name Butrans. Butrans is in the form of a patch. We will be using 5mcg/hour, 10mcg/hour, and 20mcg/hour patches that will be changed every 7 days.

Each subject will participate in this arm of the study for four weeks.

Drug: buprenorphine transdermal delivery system (BTDS)
Other Name: Butrans

Drug: Placebo for BTDS patch
A placebo patch will be manufactured to mimic the BTDS patch.




Primary Outcome Measures :
  1. The International Restless Legs Scale (IRLS) [ Time Frame: Within subjects IRLS score change after 4 weeks on placebo vs 4 weeks on BTDS ]
    The primary endpoint will be the within-subjects difference in IRLS between BTDS and placebo treatment, measured at visits 5 and 8. This comparison will be made with a fixed effects model in SAS, using PROC MIXED with a repeated statement (baseline, BTDS, placebo) to account for intra-subject correlation. Sequence, treatment, and treatment by sequence interactionterms will be included as fixed effects.


Secondary Outcome Measures :
  1. Clinical Global Impression of Improvement [ Time Frame: Evaluated after 4 weeks on placebo and again after 4 weeks on BTDS or vice versa ]
    The main secondary endpoint will be the difference between placebo and BTDS in the percentage of subjects who are "much improved" or "very much improved" on the CGI-I, evaluated using generalized estimating equations.


Other Outcome Measures:
  1. MOS Sleep Scales [ Time Frame: Evaluated after 4 weeks on placebo and again after 4 weeks on BTDS or vice versa ]
    Another secondary endpoint will be the difference between BTDS and placebo on the MOS Sleep Scales (sleep disturbance, sleep quantity, and sleep adequacy).

  2. Profile of Mood States (POMS) [ Time Frame: Evaluated after 4 weeks on placebo and again after 4 weeks on BTDS or vice versa ]
    Another secondary endpoint will be the difference between BTDS and placebo on the Profile of Mood States (POMS).

  3. RLS-QLI [ Time Frame: Evaluated after 4 weeks on placebo and again after 4 weeks on BTDS or vice versa ]
    Another secondary endpoint will be the difference between BTDS and placebo on the RLS Quality of Life Questionnaire (RLS-QLI).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   25 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject has a diagnosis of RLS, defined by International Restless Legs Study Group (IRLS) essential criteria:

    • An urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legs.
    • The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying down or sitting.
    • The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues.
    • The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur in the evening or night.
  • Subject has moderate to severe RLS symptoms,defined as an International Restless Legs Scale (IRLS) score greater than or equal to15 at the baseline visit (visit 2).
  • Subject has RLS symptoms that, in the opinion of the investigator, require round-the-clock treatment.
  • Subject speaks and reads English.
  • Subject is able to provide informed consent.
  • Subject is age ≥25 and ≤75.
  • Subject has BMI ≥18 and ≤35
  • Subject is naïve to opioid treatment, defined as subjects not having received ≥5 mg oxycodone in the past 14 days and no history of daily use of ≥5 mg oxycodone equivalents in the past 3 months.
  • If subject is currently being treated for RLS, s/he must have an inadequate response to or be intolerant of current, non-opioid regimen.
  • If subject is not currently being treated for RLS, s/he must have a contraindication to or a history of intolerance to non-opioid treatment options for RLS, concerns about side effects of such options, or a preference for non-oral medication.
  • If subject is currently being treated with a medication for RLS, a washout period of at least 3 days will be required (or 5 half-lives for longer-acting agents).
  • Subject's history and/or clinical records document no change in medications active in the central nervous system (antidepressants, analgesics, antipsychotics, antiepileptics, hypnotics, etc.) for at least 30 days prior to visit 1.
  • Subject is able to understand study procedures and agrees to remain on stable medications during the period of the study.
  • Women of childbearing potential must agree to use a medically accepted method of birth control. Acceptable forms of birth control include:
  • Condom + spermicide
  • Diaphragm + spermicide
  • Oral contraceptive pills, hormone implants (like Norplant), or injections(like Depo-Provera)
  • Intrauterine Device

Exclusion Criteria:

  • Lifetime history of DSM-IVopiod, alcohol, or other substance abuse.
  • History of opioid treatment for RLS with inadequate response
  • Positive urine toxicology screen at visit 1.
  • Another chronic pain syndrome that would, in the opinion of the investigator, interfere with evaluation of RLS symptoms or the response to the study medication.
  • Plan to undergo a procedure that may require short or long-term opiates for pain control during the course of the trial.
  • History of severe mental illness.
  • Women who are pregnant, lactating, or planning to become pregnant.
  • Shift work or other commitments that do not allow for regular sleep at night.
  • Known hypersensitivity or intolerance to opioids.
  • History of Long QT Syndrome or an immediate family member with this condition, or known prolongation of QTc interval.
  • QTc interval prolongation >500 ms on screening EKG at Visit 1.
  • History of malignant melanoma.
  • Current use of monoamine oxidase inhibitors.
  • Prior or current clinically significant impulse control disorder, as determined by clinical interview and the Modified Minnesota Impulse Disorders Interview at Visit 1.8
  • Untreated severe sleep apnea, defined as AHI >30.
  • Iron deficiency, defined as ferritin<15 at Visit 1.
  • Any dermatologic condition resulting in widespread compromise of skin integrity, defined as >50% of the surface area within the 8 sites described for BTDS application.
  • Current use of class IA or class III anti-arrhythmic medication.
  • Significant risk for suicide by clinical interview.
  • Known hypersensitivity to buprenorphine or any excipient of BTDS.
  • Current unstable medical illness.
  • Any medical or psychiatric condition that, in the opinion of the investigator, would interfere with participation in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02138357


Locations
Layout table for location information
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Investigators
Layout table for investigator information
Principal Investigator: John W. Winkelman, MD, PhD Massachusetts General Hospital (Partners Healthcare)
Layout table for additonal information
Responsible Party: John Winkelman, MD, PhD, Chief of the Sleep Disorders Clinical Research Program, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT02138357    
Other Study ID Numbers: 2013D004946
First Posted: May 14, 2014    Key Record Dates
Last Update Posted: January 7, 2015
Last Verified: January 2015
Keywords provided by John Winkelman, MD, PhD, Massachusetts General Hospital:
Restless Legs Syndrome
Willis Ekbom Disease
Twitchy Legs
Periodic Limb Movements
Leg Movements
Augmentation
Requip
ropinirole
Mirapex
pramipexole
gabapentin
Horizant
Neupro
rotigotine
Additional relevant MeSH terms:
Layout table for MeSH terms
Psychomotor Agitation
Restless Legs Syndrome
Syndrome
Disease
Pathologic Processes
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Psychomotor Disorders
Neurobehavioral Manifestations
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Parasomnias
Mental Disorders
Buprenorphine
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists